Lidamycin (LDM) is a new member of enediyne antitumor antibiotics family that can be separated and reconstituted. It consists of a labile active enediyne chromophore (AE) and a noncovalently bound apoprotein (LDP). LDM is now in phase II clinical trials. In this study, we described the antitumor features of a fusion protein of LDM, anti-CD20Fab-LDM, targeted to CD20 expressed by B-lymphoid malignancies. Especially, LDM was prepared by a novel two-step method including DNA recombination and molecular reconstitution. Anti-CD20Fab-LDM exerted potent cytotoxicity against CD20 + B-cell lymphoma cell lines in vitro (IC50: 10-30 pM) and in the Raji xenograft model. Two Raji xenografts were allowed to grow to an initial mass of 80 and 500 mm 3 , respectively, and then anti-CD20Fab-LDM was administered intravenously with the highest dose of 4 nmol kg À1 . The inhibition rates of tumor growth were 90.1 and 85%, which were saliently superior to those of nontargeted LDM. It is noteworthy that anti-CD20Fab-LDM can inhibit the growth of patient-derived cells, including rituximab-resistant patientderived cells. Thus, CD20-targeted delivery of LDM is a specific and potent therapeutic strategy for B-lymphoid malignancies. In addition, the two-step approach could serve as a new technology platform for making a series of highly potent engineered antibody-based drugs.
Introduction
The efficiency of treatments for B-lymphoid malignancies remains a seriously unmet medical need. Nowadays, B-lymphoid malignancies are the fifth most common malignancy in the world and its incidence is continuously rising. Besides, B-lymphoid malignancies tumors can relapse in B-lymphoid malignancies were observed who initially responded to treatment. Rituximab (RTX), the CD20-specific chimeric monoclonal antibody, was approved by the Food and Drug Administration in 1997, and markedly improved clinical responses in B-lymphoid malignancies were observed. Unfortunately, about 50% of patients with aggressive B-cell non-Hodgkin's lymphoma have primary refractory disease or develop relapses after treatment with RTX, whereas the efficacy of RTX is limited in B-cell chronic lymphocytic leukemia patients. 1 The success of RTX presents clear opportunity for antibody-based agents in lymphoma, although the limitations of it calls for such agents with different mechanisms. Focused delivery of the cytotoxic agent to tumor cells maximizes its antitumor effect and minimizes its normal tissue exposure, resulting in an improved therapeutic index. Moreover, antibody-targeted chemotherapeutic agent is especially effective against RTX-resistant malignant B cells that currently escape from therapy. Although the first antibody-targeted chemotherapy strategy has been applied since 1999, it had not been successfully translated into clinical benefit until the recent introduction of gemtuzumab ozogamicin, the only antibody-targeted chemotherapeutic agent approved for clinical use in the United States. 2 Gemtuzumab ozogamicin is comprised of a humanized IgG4 anti-CD33 antibody covalently linked to N-acetyl-g-calicheamicin dimethyl hydrazide, which is a member of enediyne antibiotics. 3 Enediyne antibiotics have been focused on their potent antitumor activity because of their unique ability to damage the DNA of tumor cells by inducing single-strand and/or double-strand breaks through free radical attacks on the deoxyribose moieties in DNA. Lidamycin (LDM, also designated as C1027) is a new member of the enediyne antibiotic family, which was isolated from a Streptomyces globisporus C1027 strain in China. LDM shows extremely potent cytotoxicity, antitumor activity and marked growth inhibition of transplantable tumors in mice. [4] [5] [6] [7] In terms of the half maximal inhibitory concentration (IC50) values, the cytotoxicity of LDM was 10 000-fold more potent than those of mitomycin and doxorubicin. 7, 8 Unlike calicheamicin, LDM consists of a noncovalently bound apoprotein LDP (10 500 Da), which formed a hydrophobic pocket for protecting the chromophore, and an enediyne chromophore (843 Da), responsible for the extremely potent bioactivity, which binds DNA in the minor groove and causes double-strand DNA breaks in to a thiol-dependent manner, leading to apoptosis and cell death.
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The apoprotein and chromophore can be dissociated and reconstituted, and the biological activity of the rebuilt molecule is comparable to that of nature LDM. Therefore, anti-CD20Fab-LDM can be prepared by a novel two-step method including DNA recombination and molecular reconstitution. It provided a new technology platform for making a series of highly potent engineered antibody-based drugs for a variety of cancers.
We constructed a chimeric anti-CD20Fab 0 fragment from the hybridoma cell line and demonstrated that the Fab fragment could be produced in Escherichia coli in soluble form with good retention of antigenbinding activities. 12 In this study, we developed a two-step approach to construct a new fusion protein, anti-CD20Fab-LDM. First, the fusion protein antiCD20Fab-LDP that is composed of the apoprotein LDP of LDM and Fab from anti-CD20mAb was prepared by recombinant DNA techniques. Second, the energized fusion protein anti-CD20Fab-LDM was prepared by molecule reconstitution, that is, putting the active enediyne chromophore into anti-CD20Fab-LDP. Importantly, anti-CD20Fab-LDM resulted in a superior antitumor activity compared with LDM: this fusion protein showed extremely potent cytotoxicity to B-cell lymphoma and marked antitumor activity in vivo. In contrast, anti-CD20Fab-LDM lacked systemic toxicity in nude mice. The efficient antitumor activity of antiCD20Fab-LDM made it a treatment option for B-lymphoid malignancies.
Results

Construction and production of the fusion protein
To achieve the fusion protein, the DNA sequence encoding for the CH1 fragment of the anti-CD20Fab was genetically fused to the LDP gene, which encodes for the apoprotein of LDM, with a five-amino-acid spacer (GGGGS) between the C-terminus of CH1 and the N-terminus of LDP, and cloned into the ApaI/SphI restriction sites of the expression vector ( Figure 1a) . The soluble fusion protein was released from the periplasmic space of E. coil strain HB2151 containing the expression vector by osmotic shock and purified with a protein G tag affinity chromatography. The yield of the purified fusion protein in the shaker flask was about 4-5 mg l À1 media from an overnight culture.
SDS polyacrylamide gel electrophoresis and western blot analysis of the fusion protein
The fusion protein was analyzed on 12% SDS polyacrylamide gel electrophoresis under nonreducing and Anti-CD20Fab-LDM inhibited B-cell lymphoma xenografts C Xin et al reducing condition. In nonreducing condition, the purified fusion protein yielded a single protein band of expected size; however, under the reducing condition, the band at 62 kD was resolved into two protein bands with the calculated molecular weights of 39 and 23 kD, because the disulfide bond was broken (Figure 1b) . Western blot analysis using a mouse anti-LDP antibody confirmed the existence of the 62-kD fragment, which contained LDP fragment ( Figure 1c ). These results indicated that the purified expression product was anti-CD20Fab-LDP fragment. The fusion protein was not detected in the flow through fraction, suggesting high efficiency of the purification process.
CD20-specific binding in vitro
Flow cytometry was carried out to confirm the CD20-specific binding of the fusion protein. Incubation of CD20-positive Raji cells with different concentrations of anti-CD20Fab-LDP resulted in specific binding. Similar affinity data were obtained with anti-CD20Fab ( Figure 2 ). This further confirmed that fusing an LDP to anti-CD20Fab did not have an obvious impact on the ability of the fusion protein to bind the surface of CD20-positive cells.
In vivo targeting and accumulation of the fusion protein
In vivo distributions of the fusion protein were observed in nude mice bearing the Raji or K562 xenografts.
In vivo fluorescein isothiocyanate (FITC)-labeling of nude mice revealed that fusion protein penetrated into CD20-positive tumors within 1 h after intravenous (i.v.) injection (16 nmol per mouse) and then gradually accumulated in the tumor cores. Such accumulation spread to the whole tumor area within 3 h after injection, but no similar accumulation was noticed in CD20-negative tumors. At 8-10 h after injection, anti-CD20Fab and anti-CD20Fab-LDP still remained in the tumors, whereas the labels had been cleared from other areas. In contrast, there was hardly any accumulation of LDP (16 nmol per mouse) in tumors ( Figure 3 ). Collectively, our data strongly suggested that the targeting specificity of the fusion protein had driven their selective accumulation in the cores of solid tumors after i.v. injection.
Preparation of energized fusion protein anti-CD20Fab-LDM
The energized fusion protein anti-CD20Fab-LDM was prepared by adding AE, the active enediyne chromophore of LDM, to anti-CD20Fab-LDP solution in controlled conditions, followed by separating from free AE by the sephadex G-75 column (Amersham Bioscience, Arlington Heights, IL, USA). As shown in Figure 4 , the correct antiCD20Fab-LDM molecules showed strong absorbance at both 340 and 280 nm, which represents the absorbance of the chromophore and protein moiety, respectively.
CD20-restricted killing activity in vitro
The effects of CD20-specific anti-CD20Fab-LDM on the growth of CD20-positive cell lines and patient-derived cells were examined in 72 h in vitro culture assays. LDM was used as a nonbinding control to explore antigennonspecific effects. Anti-CD20Fab was also used to assess the sensitivity of these cell lines to LDM (not shown). Adriamycin (ADR) was as a positive drug control. As shown in Figure 5 , the cytotoxicity of antiCD20Fab-LDM was 10 000-fold more potent than that of ADR. Especially, CD20-positive cells exhibited greater sensitivity to anti-CD20Fab-LDM than CD20-negative cells, and anti-CD20Fab-LDM exerted a 6-to 10-fold more potent growth inhibitory effect on those of the CD20-positive cell lines than LDM (Po0.05). Of note, in most cell lines tested, anti-CD20Fab-mediated killing did not exceed 10% even at the presence of the highest concentration (0.01 mmol l À1 ). And antiCD20Fab-LDP also exerted a 5-to 8.9-fold more potent growth inhibitory effect on primary patient-derived tumor B cells than LDM (Table 1) .
Effects of the fusion protein on growth of subcutaneous xenografts
Anti-CD20Fab-LDM was examined for its efficacy against subcutaneous Raji xenografts established in nude mice. LDM was used as a nonbinding control. The mice were administered i.v. with 4 nmol kg
anti-CD20Fab and phosphate-buffered saline (PBS) (vehicle) (Q1W Â 2). Tumors were allowed to grow to an initial mass of 40-60 mm 3 (small size, Figure 6a ) or 450-500 mm 3 (large size, Figure 6b ) before the initiation of therapy. The anti-CD20Fab-LDM inhibited the subcutaneous growth of Raji xenografts in a dose-dependent manner. Mice treated with LDM at tolerated dose of 4 nmol kg
À1
showed an inhibition rate of 65 (small size) and 62% (large size). The anti-CD20Fab-LDM at the same concentration suppressed the tumor growth by 90.1 (small size) and 84.5% (large size), which demonstrated statistically significantly differences (Po0.05) compared with those of LDM in each of the studies, regardless of the initial tumor mass. Almost no therapeutic benefit could be achieved in the group treated with 4 nmol kg anti-CD20Fab. The same conclusion was shown in Figure 6 , the tumor volume of mice treated with LDM at tolerated dose of 4 nmol kg À1 was two-to fourfold more potent than that of anti-CD20Fab-LDM. During the ; n ¼ 3.
Anti-CD20Fab-LDM inhibited B-cell lymphoma xenografts C Xin et al experiment, mice in all groups were observed with no significant adverse reactions, such as lethargy and anorexia.
Anti-CD20Fab-LDM lacks toxicity in nude mice
As it is shown in Figure 7 and Table 2 , anti-CD20Fab-LDM lacked systemic toxicity in nude mice. In contrast, treatment with LDM (4 nmol kg
À1
) was associated with some toxicity in mice with weight loss; an 8% damages the liver, a 4% damages the spleen and a 4% damages the kidney. Nude mice in this study were exposed to total body irradiation (400 rad) to further suppress their residual immune system, so data were toxic than Kunming mice without irradiation.
Discussion
We explored a CD20-specific fusion protein antiCD20Fab-LDM. The therapeutic strategy targeting Images showed that within 1 h after injection, anti-CD20Fab and antiCD20Fab-LDP penetrated into the CD20-positive tumor then gradually accumulated in the core area of the tumor. At 8-10 h after injection, anti-CD20Fab and anti-CD20Fab-LDP still remained in the tumors, whereas the labels had been cleared from other areas. But no similar accumulation was observed in CD20-negative tumors. Images showed that LDP could also penetrated into the whole tumor either CD20-positive or CD20-negative tumors, but hardly any accumulation of LDP was observed in tumors at 8-10 h after injection; n ¼ 5.
Anti-CD20Fab-LDM inhibited B-cell lymphoma xenografts C Xin et al CD20 has been extensively exploited for years with a number of antibody invented, conjugated or not, and some of them are already in the first line of clinical use. Yet the improvements in this area are still in pressing need.
In this study, we developed a new way of CD20-targeting therapy by exploiting the anti-CD20Fab-LDM, which exhibited a potent, dose-dependent cytotoxicity against CD20 + B-lymphoma cells. Primarily, we systematically assayed the validity of the fusion protein's bioactivity. As the potency is concerned, with the IC50 value of only 10-30 pM, it was 10 000-fold more potent than that of ADR. Theoretically, only one copy of it is enough to kill a cancer cell. 6, 13 AntiCD20Fab-LDM also caused a dose-dependent regression of Raji xenografts grown as subcutaneous solid tumors in athymic nude mice. It was effective not only in the initially established Raji xenografts, but also in preexisting large established ones. The inhibition rates of tumor growth were 90.1 and 84.5%, respectively, with the concentration of anti-CD20Fab-LDM up to 4 nmol kg
À1
. Whereas those of non-targeted LDM were only 65 and 62%, respectively. Further, anti-CD20Fab lacked antitumor activity at the dose evaluated. The data indicated that both the targeting moiety and the 'warhead' moiety of the fusion protein served their duty as expected.
The anti-CD20Fab-LDM was successfully constructed as an extremely potent and specific antitumor fusion protein with tolerable systematic toxicity to eradicate the target malignant B cells.
Especially, anti-CD20Fab-LDM is innovative and noteworthy in that it simultaneously circumvented several mechanisms that were held primarily responsible for RTX resistance. To our knowledge, it is the first time that all these valuable features, together with highly specific and potent antitumor activity, were artificially integrated into one single molecule.
First, anti-CD20Fab-LDM is effective against the effector exhaustion. The therapeutic effect of RTX depends on the host immune effector system, including effector cells (natural killer (NK) cell, mediate antibodydependent cell-mediated cytotoxicity (ADCC) effect) and molecules complement-depend cytotoxicity effect (CDC), continuous administration of RTX and high tumor burden can exhaust host effector function and nullify the effect of RTX. Fischer et al.
14 reported that NK-cellmediated ADCC of RTX-opsonized cells promotes upregulation of CD107a, a marker of degranulation and presumably cell exhaustion. Berdeja et al. 15 found that ADCC may be significantly reduced owing to high burdens of RTX-opsonized cells. Kennedy et al. 16 reported that RTX infusion in chronic lymphocytic Anti-CD20Fab-LDM inhibited B-cell lymphoma xenografts C Xin et al leukemia patients depleted complement. It seems that new strategy independent of host immune system should avoid this problem. The radiolabelled antibodies, Y-90 ibritumomab tiuxetan (Zevalin, Biogen-IDEC, Cambridge, MA, USA) and I-131 tositumomab (Bexxar, Glaxo Smithkline, Middlesex, British), exert effects dependent on b-emissions with path lengths of 1-5 mm, and thus avoided the effector exhaustion problem of RTX, but g-radiation is the new safety issue, which can damage nearby progenitor cells in bone marrow, and cause pancytopenia. Sublethal radiation damage to bone marrow stem cells increases the risk of myelodysplastic syndrome and/or acute myelogenous leukemia. 17 Interestingly, the anti-CD20Fab-LDM elicit cytotoxicity through the conjugated LDM without any g-radiation, rather than ADCC or CDC effects, which depends on the host effector system, and therefore avoids the effectorexhaustion problem, which hampered the efficacy of RTX.
Second, anti-CD20Fab-LDM is effective against 'shaving of CD20', which refers to the phenomenon that soon after the clearance of circulating RTX-opsonized B cells, additional malignant B cells enter blood stream from other compartments, and CD20 are removed ('shaved') from these cells. 16, 18, 19 This was mediated by the interaction between the Fc fragment of RTX and Fc-g receptor I of monocytes and macrophages; data indicate that F(ab 0 ) 2 of RTX effectively avoided the problem, 20 indicating that removal of Fc fragment from the CD20-targeting antibody is a solution for shaving of CD20. We adopted CD20-Fab fragment as the targeting moiety of the fusion protein; compared with the whole antibody, Fab downsized the molecule weight while retaining the binding specificity, and most importantly, with the Fc fragment deleted, the CD20-Fab-LDM successfully avoided the 'shaving of CD20' phenomenon, which is mediated by the Fc-FcR interaction. Anti-CD20Fab-LDM inhibited B-cell lymphoma xenografts C Xin et al
Finally, anti-CD20Fab-LDM is effective against BCL-2 overexpression. Raised apoptosis threshold by BCL-2 overexpression is considered a major cause of RTX resistance. The crosslink of CD20 receptors by RTX can trigger caspase3-dependent apoptosis signaling, which can be hampered by the overexpression of anti-apoptotic BCL-2. Combination of antisense BCL-2 oligonucleotides can enhance the efficacy of RTX. 21 Oblimersen sodium, a BCL-2 antisense oligonucleotide, is under phase II trial in combination with RTX in patients with recurrent B-cell non-Hodgkin's lymphoma, 22 which holds out the promise of combination therapy with anti-CD20 and BCL-2 expression suppressing method. It is reported that LDM alone is able to suppress the expression of BCL-2, 23 the same effect obtained by the management of BCL-2 antisense nucleotide. According to our own experiment (data not shown), with conjugated LDM, anti-CD20Fab-LDM can efficiently circumvent the upregulated apoptosis threshold mediated by BCL-2 overexpression, which have been hindering the effect of RTX. And therefore the conjugated LDM can facilitate the apoptosis induction effect conducted by the crosslink of CD20 receptors, upon binding of anti-CD20Fab-LDM or RTX.
With all above-mentioned exceptional antitumor application features, anti-CD20Fab-LDM is especially easy and economical to produce, in the unique way we constructed and expressed it. Productivity and feasibility are also important in the manufacture of antibody product, especially in consideration of the future industrialization. Immunotoxins containing chemical conjugates of ligand and toxin were often difficult to produce because the ligand and toxin had to be purified separately, the conjugation procedure is difficult with low yield, and the junction between the toxin and ligand could be at many different sites (for example, at any lysine residue). And percentage of the conjugate product would have an inappropriate toxin: ligand ratio, and consequently would suffer from inactivity. In contrast to those antibody conjugates linked by chemical reaction, our way preserve the high-order structure and activity of the Fab, and easily obtained the perfect 1:1 antibody-effector ratio in the final products. Data indicated fusing an LDP to anti-CD20Fab did not have an obvious impact on the ability of the fusion protein to bind to the surface of CD20-positive cells. The affinity constant of anti-CD20Fab and anti-CD20Fab-LDP were 0.10eÀ9 M À1 and 0.11eÀ9 M
. In vivo images showed that within 1 h after injection, anti-CD20Fab and antiCD20Fab-LDP both penetrated into the CD20-positive tumor then gradually accumulated in the core area of the tumor within 3 h.
Besides, we innovatively constructed the CD20-Fab fragment and the apoprotein of LDM into one fusion protein, which was expressed in E. coli solubly. To our knowledge, anti-CD20Fab-LDP is the first soluble expression of CD20-Fab with prokaryote. Compared with eukaryote expression systems, which were used by many merchandised monoclonal antibodies or other antibody products, the prokaryote expression is far more suitable for massive production, in that the condition management is simpler and the cost is much cheaper. In general, insufficient and costly production of monoclonal antibodies using conventional technology has severely hampered the clinical evaluation of these reagents. Expression of these molecules in E. coil can improve the clinical application, therefore expressing and purifying anti-CD20Fab-LDM seems to be an attractive and feasible approach for experimental and clinical tumor therapy.
In our study, we obtained the energized fusion protein anti-CD20Fab-LDM by molecular reconstitution; the anti-CD20Fab-LDP fusion protein were integrated with an active enediyne chromophore. The molecule of the energized fusion protein anti-CD20Fab-LDM contains three parts, including anti-CD20Fab, LDP and AE, and each of them has different roles in exerting the biological function of the whole molecule. The Fab portion of anti-CD20 antibody serves as a tumor-targeting vehicle, and the active enediyne AE serves as a 'warhead' with highly potent cytotoxicity. In addition, LDP works as a carrier for AE by offering a hydrophobic pocket. As expected, we successfully integrated the abovementioned activities into one single energized fusion protein of anti-CD20Fab-LDM. The chomophore released from the holoprotein is highly labile, the LDM has to enter target cell in the form of holoprotein, and bind to the minor groove of the DNA strands, thus the chromophore is released sufficiently close to extract hydrogen from ribose rather than other sources, to break the DNA strands. Therefore the pre-binding release of the chromophore is ineffective, in that way, the specificity of the ultracytotoxicity of the conjugated LDM is ensured. 24 Obviously, the anti-CD20Fab-LDM is in superior advantage to unconjugated LDM in terms of specificity. Anti-CD20Fab-LDM exerted potent cytotoxicity against CD20 + B-cell lymphoma cell lines (inhibitory concentration of 50%: 10-30 pM) and retarded the growth of Raji in mice. All these demonstrated that AE was added Tissue injury was measured by the area ratio of lesions versus total on the tissue surface.
Anti-CD20Fab-LDM inhibited B-cell lymphoma xenografts C Xin et al accurately into the hydrophobic pocket of apoprotein LDP and indicated that anti-CD20Fab-LDM has super antitumor activity in contrast with the same concentration of LDM. Moreover, much of the data addressing CD20-targeted immunoconjugate of enediyne antibiotic comes from assays with cell lines, and the relevance to activity in patients remains uncertain. In this report, we demonstrated firstly that anti-CD20Fab-LDM can inhibit the proliferation of primary patient-derived malignant B cells and, its inhibition was even effective in one relapsed patient after 2-year standard RTX therapy. Hence, our data provide evidence for the therapeutic potential of anti-CD20Fab-LDM, which may help those RTXresistant patients.
In summary, we successfully constructed and expressed the fusion protein of anti-CD20Fab-LDM, which transported the potent antitumor agent LDM to the valuable target CD20. The fusion protein exhibited satisfying specificity and cytotoxicity both in vitro and in vivo. Its unique structure and feature successfully solved several shortcomings in conventional CD20-targeting therapeutics, similar to 'host effector exhaustion', 'shaving of CD20' and BCL-2-mediated apoptosis resistance. The fusion protein was expressed solubly with high yields in E. coli at low cost and possessed highly potent activity. The anti-CD20Fab-LDM provides a promising new solution for anti-CD20 therapies, its construction and expression revealed a new technique routine for exploring antibody-based and tumor-targeting fusion protein for cancer therapy.
Materials and methods
Cell lines
The B-cell lymphoma line, Raji, Daudi and chronic myelogenous leukemia cell line K562 were cultured in RPMI-1640 supplemented with 10% fetal calf serum at 37 1C in humidified 5% CO 2 atmosphere.
Isolation of primary patient-derived malignant B cells
Blood were obtained from four patients with B-lymphoid malignancies (three newly diagnosed and one relapsed) granting informed consent as approved by the Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Institutional Review Board. Mononuclear leukocytes were separated with Ficoll from patient peripheral blood and were analyzed by incubating with FITC-conjugated anti-CD19 antibody, phycoerythrin -conjugated anti-CD20 antibody and FITC-/phycoerythrinconjugated polyclonal human IgG as a nonbinding control (BD Biosciences, San Jose, CA, USA). Only CD20-positive cells in the CD19-positive cells accounted for more than 95%, CD19-positive cells were sorted by BD FACSAriaII Cell-Sorting System u sing a FITCconjugated anti-CD19 antibody. Incubations were carried out for 0.5 h at room temperature and were followed by washing twice with serum-free medium.
Animals
Female nude mice (5-6 weeks old) (BALB/C, nu/nu, body weight 16-18 g) were obtained from the Vital River Laboratories (Beijing, China).
Construction of anti-CD20Fab-LDP
The first antibody heavy chain constant domain (CH1) gene of the anti-CD20 antibody and the LDP gene were cloned from vector pCANTAB 5E-Fcd20Fab 0 and pGEMT-LDP as previously described, 12 and then the synthetic DNA sequence encoding CH1-LDP was generated by Splicing by Overlapping Extension PCR (SOE PCR) technology using the CH1 and LDP genes. The CH1 and LDP sequences were genetically linked through a flexible peptide linker (GGGGS). Moreover, restriction enzyme sites ApaI (GGCCCA) and SphI (GCATGC) were added to the 5 0 -end and 3 0 -end of this sequence, yielding a 669-bp DNA fragment designated ApaI-CH1 LDP-SphI. After digestion with ApaI and SphI, this fragment was cloned into the vector pCANTAB 5E-Fcd20Fab 0 , which contained the variable heavy chains (VH), the variable light chains (VL) and the antibody light chain constant domain (CL) gene of the anti-CD20 antibody, yielding a plasmid named pCANTAB 5E-CD20Fab-LDP.
Expression and purification of the fusion protein
This fusion protein was secreted from E. coli strain HB2151 containing the expression plasmid grown at 30 1C in the shaker flask following a procedure previously described. 25 A periplasmic extract of the bacteria was prepared by resuspending the bacteria pellet in 25 mM Tris (pH 7.5) containing 20% (w/v) sucrose, 200 mM Nacl and 1 mM EDTA, followed by incubation at 4 1C with gentle shaking for 1 h. After centrifugation at 12 000 r.p.m. for 15 min, the soluble antibodies were purified from the supernatant by a protein G tag affinity chromatography using the RPAS Purification Module (Amersham Bioscience). The endotoxin level of the purified antibody preparations was assayed routinely before their use in any in vitro and in vivo studies.
SDS polyacrylamide gel electrophoresis and western blot analysis of the fusion protein
The E. coli periplasmic extract and the purified fusion protein preparation were electrophoresed in a 12% polyacrylamide gel and visualized by staining with Coomassie brilliant blue. In addition, an identical gel was transferred onto polyvinylidene difluoride (PVDF) membranes and subjected to western blot analysis using a mouse anti-LDP antibody (3H8) and a rabbit antimouse IgG antibody conjugated with horseradish peroxidase (Bejing Zhongshan Golden Bridge Biotechnology Co. Ltd, Beijing, China). All signals were detected by using enhanced chemiluminescence (Amersham Bioscience).
In vitro CD20-specific binding of the fusion protein Anti-CD20Fab-LDP and anti-CD20Fab were labeled with FITC (EZ-labeled FITC protein labeling kit, Pierce Biotech, Rockford, IL, USA). CD20-specific bindings of the fusion protein were analyzed by flow cytometry. Briefly, about 1 Â 10 6 Raji lymphoma cells were incubated with varying concentrations of FITC-conjugated fusion protein, anti-CD20Fab or polyclonal human IgG as a nonbinding control in a final volume of 0.2 ml. Incubation was continued for an additional 60 min on ice. After two washes with serum-free medium, the cells were analyzed by flow cytometry.
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In vivo targeting and accumulation of the fusion protein
Female, 5-to 6-week-old nude mice were exposed to total body irradiation (400 rad) to further suppress their residual immune system and facilitate the establishment of xenografts. After 12 h, the mice were injected subcutaneously with 2 Â 10 7 Raji or K562 cells suspended in PBS in the right flank. Mice with staged tumors (0.1 g) were administered i.v. with FITC-labeled anti-CD20Fab-LDP, anti-CD20Fab or anti-LDP (16 nmol per mouse). 26 The mice were imaged using the previous procedure to monitor the distributions of the fusion protein at different time points. 27 Preparation of energized fusion protein anti-CD20Fab-LDM LDM (10 mg) with high potent activity were suspended in 5 ml methanol and whisked for 5 min at 4 1C, and then the mixture was placed at 20 1C for 1 h. AE was obtained from the supernatant of reaction mixture by centrifugation at 16 000 r.p.m. for 20 min at 4 1C. The above procedure was repeated once to isolate AE completely. For obtaining energized fusion protein anti-CD20Fab-LDM, AE in methanol was added to anti-CD20Fab-LDP/ PBS (10 mmol l À1 , pH 7.0) with the molecular ratio of 5:1 and the volume ratio of 1:50, respectively, and then placed at room temperature for 12 h. Purified antiCD20Fab-LDM was prepared finally by separating from free AE by using a sephadex G-75 column.
In vitro CD20-restricted killing activity of the fusion protein CD20-positive Daudi, Raji, Ramos cells or leukocytes from patients with non-Hodgkin's lymphoma or ALL (for individual characteristics, see Table 1 ) cells were seeded at 2 Â 10 4 per well in a 96-well plate, and CD20-negative K562 cells were used as a nonbinding control. Then different concentrations of anti-CD20Fab-LDM, LDM and ADR were added and incubated for 72 h. The effects on cell growth were examined by (4, 5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Briefly, 20 ml of MTT solution (5 mg ml
À1
) was added to each well and incubated at 37 1C for 4 h. The supernatant was removed and cells were dissolved in 100 ml of dimethylsulfoxide, and then monitored with a microplate reader at a wavelength of 546 nm. Survival ratio was calculated according to the following formula: survival ratio ¼ (A test ÀA blank )/(A control ÀA blank ) Â 100%.
